Glooko has raised $172.0M in total across 7 funding rounds.
Glooko's investors include Canaan Partners, Jlabs, rocketship.vc, Social Capital, Tribe Capital, Bill Campbell, Sundeep Madra, Atreides Management, Bowery Capital, Colle Capital, Flexcap, Greylock.
# Glooko: A Technology Company Transforming Diabetes Care
Glooko is a digital health platform company that centralizes diabetes management data and connects patients, healthcare providers, and medical devices to improve clinical outcomes and reduce costs.[1] The company builds software that integrates data from more than 200 diabetes and health monitoring devices into a unified platform, eliminating fragmented workflows and manual data entry that burden clinicians and patients alike.[1][2]
Glooko serves three primary constituencies: people living with diabetes (through a free mobile app), healthcare providers and clinics (through clinical decision-support tools), and hospitals and health systems (through EHR integrations and population health analytics).[1] The core problem it solves is the inefficiency and complexity of diabetes care delivery—clinicians previously had to navigate multiple devices with different connection cables and data displays, while patients struggled to understand their condition across disconnected systems. By creating a seamless, integrated platform, Glooko enables clinicians to spend less time on administrative tasks and more time on patient care, while helping patients achieve better glycemic control and health outcomes.[2][4]
The company has demonstrated strong growth momentum, recently completing a Series F funding round and acquiring Monarch Medical Technologies to expand its capabilities into inpatient insulin dosing.[3][6] In 2025, Glooko was recognized as one of the Top 50 Healthcare Technology Companies, reflecting its leadership position in the digital diabetes management space.[7]
Glooko was founded in the summer of 2010 and launched its first product in November 2011: the MeterSync Cable and Glooko Logbook app for iOS, which allowed users to download glucose meter readings into a mobile app with a simple $40 cable.[4] This founding insight—that diabetes patients were struggling with disconnected devices and manual data management—proved prescient and addressed a genuine pain point in the market.
The company achieved early traction by solving a critical interoperability problem. In 2014, Glooko launched MeterSync Blue, introducing Bluetooth connectivity to tens of millions of blood glucose meters without requiring physical cables.[4] A major inflection point came when Glooko persuaded Medtronic to allow backend accessibility through its proprietary CareLink software, a significant win given the large installed base of Medtronic users.[4] By 2015, the platform was compatible with 35+ meters and accessible on both Apple and Android devices.[4] The company subsequently obtained FDA approval for a long-acting insulin titration app for type 2 diabetes and began developing predictive analytics tools with AI capabilities.[4]
Glooko's platform connects more than 200 diabetes and health monitoring devices, far exceeding competitors' integration breadth.[1][2] This extensive compatibility eliminates the need for patients and clinicians to switch between multiple platforms.
The platform integrates seamlessly with major electronic health record systems including Epic, Oracle Health, MEDITECH, Greenway Health, eClinicalWorks, NextGen, and Athenahealth.[2] This deep EHR integration reduces administrative burden and ensures documentation supports CPT code reimbursement and compliance requirements.[2]
Glooko's connected care platform delivers measurable health improvements, including HbA1c reductions of up to 1.5%, decreased average blood glucose, increased time in range, and fewer hypoglycemic events.[5] These clinical results translate directly into cost savings and improved value-based care performance for health systems.[2]
Through the acquisition of Monarch Medical Technologies and its EndoTool Glucose Management System, Glooko is positioned as the only diabetes management company connecting both outpatient and inpatient care—from home to hospital and back again.[3] This end-to-end approach enables seamless transitions and more comprehensive patient management.
Glooko offers its mobile app for free to all users, removing financial barriers to adoption and enabling widespread access across diverse patient populations.[4]
Glooko operates at the intersection of several powerful healthcare trends: the shift toward value-based care models, the digitization of chronic disease management, and the growing emphasis on interoperability in healthcare IT. As health systems face mounting pressure to reduce costs while improving outcomes, integrated diabetes management platforms address a critical gap—diabetes is one of the most expensive chronic conditions to manage, yet care remains fragmented across multiple disconnected systems.
The timing is particularly favorable. Health systems are actively seeking scalable, interoperable digital solutions to support diverse patient populations and clinical workflows, as evidenced by Glooko's expansion across geographies including EMEA.[6] The regulatory environment increasingly favors interoperability (reflected in FDA and CMS policies), which plays directly to Glooko's strengths. Additionally, the rise of AI and predictive analytics in healthcare creates opportunities for Glooko to move beyond data aggregation toward proactive, personalized care—a capability the company is actively developing.[5][6]
Glooko's influence extends beyond its direct customers. By demonstrating that connected care platforms can deliver measurable clinical and financial value, the company is helping reshape expectations around how diabetes care should be delivered, influencing competitors and setting new standards for digital health integration in chronic disease management.
Glooko is well-positioned to become the dominant platform for diabetes management across the full care continuum. The company's strategic acquisition of Monarch Medical Technologies signals ambition to move beyond outpatient management into hospital settings—a significant market expansion opportunity. Looking ahead, three trends will likely shape Glooko's trajectory:
AI-Driven Personalization: The company is investing in advanced analytics and decision support tools that could shift clinicians from generalized treatment plans to highly personalized management strategies grounded in real-time data.[5] This capability will become increasingly valuable as health systems compete on outcomes.
Global Expansion: Glooko's momentum in EMEA, including the launch of Glooko XT with enhanced gestational diabetes management, suggests the company sees significant runway in international markets where digital health adoption is accelerating.[6]
Value-Based Care Integration: As healthcare payment models shift toward value-based arrangements, Glooko's ability to demonstrate cost savings and improved quality measures will become a key competitive advantage and growth driver.[2]
The company's journey from a simple cable connecting glucose meters to a comprehensive, AI-enabled platform spanning inpatient and outpatient care reflects both the evolution of digital health and Glooko's ability to anticipate and solve real problems in diabetes management. As the company continues to expand its capabilities and geographic footprint, it will likely play an increasingly central role in how diabetes care is delivered globally.
Glooko has raised $172.0M across 7 funding rounds. Most recently, it raised $100.0M Series F in October 2024.
